Randomised Phase III Trial Data on the Efficacy and Safety of Cemiplimab as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Wednesday, 12 May 2021

19:30-20:30 CEST

Welcome and introduction, Scientific background and context

Susana Banerjee, Royal Marsden Hospital, London, UK

EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

Krishnansu S. Tewari, University of California Irvine, Orange, CA, USA

Critical analysis and perspectives

Mansoor Mirza, Rigshospitalet, Copenhagen, Denmark

Discussion and Q&A (i)

Faculty and online audience

Thursday, 13 May 2021

13:15-14:15 CEST (19:15 HKT / 20:15 JST / 21:15 AEST)

Webcast of 12 May presentations, Discussion and Q&A (ii)

Faculty and online audience:

Keiichi Fujiwara, Saitama Medical University International Medical Center, Saitama, Japan

Krishnansu S. Tewari, University of California Irvine, Orange, CA, USA

Hextan Yuen-Sheung Ngan, University of Hong Kong, Hong Kong, China

David Tan, NUHS - National University Health System, Singapore